Resverlogix Corp. (FRA:RFS)

Germany flag Germany · Delayed Price · Currency is EUR
0.0825
-0.0035 (-4.07%)
Last updated: Dec 4, 2025, 8:04 AM CET
161.90%
Market Cap 22.09M
Revenue (ttm) n/a
Net Income (ttm) -6.05M
Shares Out n/a
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.0825
Previous Close 0.0860
Day's Range 0.0825 - 0.0825
52-Week Range 0.0190 - 0.1580
Beta n/a
RSI 68.22
Earnings Date Nov 17, 2025

About Resverlogix

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Donald McCaffrey
Employees 19
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RFS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.